Sign up
Pharma Capital
EPIC: CPT
Market: LSE
52-week High/Low: 9.37p / 2.20p
Sector: Health Care, Equipment & Services
Market Cap: 5.27M
Website:

Concepta is a UK- based Women’s Healthcare company which has been founded to help women with unexplained infertility to conceive.

Typically, medical intervention for infertility does not start until 12 months of a woman unsuccessfully trying to conceive, with IVF only being offered after two years of trying to conceive in most countries.

Research indicates that couples start to take...

Concepta

Interactive graph

col 3
col 4
col 5
col 6

Big picture - Why invest in Concepta

Concepta Snapshot

Growth Strategy

  • Continue the manufacture, marketing and R&D of MyLotus product, the proprietary fertility and pregnancy monitoring device
  • Market and distribute into China in 2016 – market demand has been identified
  • Roll product out through Europe – targeting UK and German markets first
  • Increase market penetration in China and Europe and look to expand into new territories
  • Utilise IP to develop other home-health monitoring products for wider family unit to improve individual health parameters incl. chronic stress, inflammation et al.

business-model

 

 

 

 

Our flagship product MyLotus has a unique offering, allowing women to see YES / NO results as well as their actual and personal level of factors that can have a direct influence on fertility – MyLotus is the only home-test on the market that currently offers this.

MyLotus has the ability to quantify personal hormone levels enabling the identification of the fertile period for a large number of women, especially for the significant amount of women whose hCG and LH levels vary from mean levels.

MyLotus addresses the issue of timing of intercourse in relation to your fertility hormones.

It can detect the actual concentration of the hormones in a woman’s urine sample allowing detailed analysis into issues with ovulation and fertility that aren’t available with other home tests on the market. This kind of data highlights the key dates in the cycle when the woman is the most fertile, improving chances of conception as well as potential areas where the woman can seek specialised medical advice.

 

 

myLotus
Ovulation Test

To get pregnant, you need to release a mature egg each month. This is called "ovulation“. We can track a certain hormone, the Luteinising Hormone (LH), that is the most reliable indicator of impending ovulation. Your LH base levels are usually low during your cycle. LH begins to surge just prior to ovulation. The peak in LH levels triggers ovulation, which occurs approximately 24-48 hours later. It is this hormone that we test, as it provides accurate information on your most fertile days giving you the highest possible chance of getting pregnant.

 

Women, who have a low base level of LH could have an LH surge that is below the average and therefore do not detect their fertile period with conventional tests, so being able to test the LH hormone concentration levels with myLotus is a huge benefit.

The tests are wrapped in protective aluminium foil and a plastic cup and pipette are provided for collecting and testing your urine. Nowadays most women are used to a midstream urine test format. myLotus takes away the common concern of whether too much or too little urine was sampled. We provide a pipette with every test and you will apply the same volume of urine each time.

myLotus is suitable for all women.

myLotus
Pregnancy Test

To check whether your are pregnant the myLotus Pregnancy (hCG) Tests (sold separately) measure the presence of the pregnancy hormone human Chorionic Gonadotropin (hCG) in your urine.

Like other pregnancy tests the product can pick up a pregnancy early. The myLotus Pregnancy Tests are over 99% accurate at detecting pregnancy from the day the period is due.

myLotus fertility

myLotus pregnancy test

FERTILITY APP

The myLotus Fertility App is a free downloadable app that helps you track your fertile days on your mobile.

It can be used as a stand alone fertility tracker or in combination with the myLotus Fertility Monitor to add real personalised data to the tracker.

The myLotus Fertility Monitor will prompt you when to carry out an ovulation or pregnancy test. The test results can then be loaded into the app for easy reference and monitoring.

The myLotus Fertility App provides valuable information for your doctor to help you improve your chances to conceive. Especially if you have low or high base levels of LH, the myLotus Fertility App will help you to identify your own hormone concentration profile and if you are ovulating: your LH surge.

 

Matthew Walls
Executive Chairman

Matthew was appointed Chairman of Concepta in July 2018 and brings extensive senior and board-level experience in public companies, particularly in pharmaceutical, diagnostics and biotech. Matthew was most recently Chief Executive Officer and Chairman of the leading international patient behavioural change company, Atlantis Healthcare Group from 2015 until 2018.

Matthew has held Chairman and advisory roles since 2013 for The Fertility Partnership, which has grown to become the UK’s largest fertility group; Matthew was previously Non-Executive Director and Chairman of Artificial Intelligence start-up, BioBeats Group Limited from 2016 until 2018; and Chief Executive Officer of AIM-listed molecular diagnostics company Genedrive Plc between 2007 and 2015, where he led the admission of the Company to AIM with the Company attaining ‘Technology Company of the Year’ in 2009 and 2015.

Matthew has also held the role of Chief Executive Officer at Oxford Biosignals Limited, Internexus Group Limited and Supanet Limited, and Zylepsis Limited between the years of 2000 and 2006 and was previously Global Commercial Director at the biopharmaceutical company AstraZeneca Plc where he was commercially and financially responsible for strategy and international business operations.

 

Erik Henau
Chief Executive Officer

. In excess of 35 years global sales and marketing experience gained in OTC medical devices including laboratory diagnostics and life sciences
. Experience at Amersham International and Oxoid in a clinical environment as well as at Unipath and Alere as the International OTC Director
. Set up Adaxis Limited which operated in the sexual and reproductive health area to commercialise innovative products in the medium term

 

Barbara Spurrier
Chief Financial Officer

. Fully qualified certified accountant (FCCA) with over 35 years finance experience in numerous sectors
. Main board director on four AIM quoted Plc’s, heading the revenue recognition committee of the board for one of these companies

 

Peter Dines
Non-executive Director

. COO and Head of Life Sciences at Mercia Technologies Plc and has particular expertise in commercialising and scaling medtech companies.
. Previously MD of obstetric and orthopaedic medical device company Surgicraft before founding and ultimately successfully exiting spinal and orthopaedic implant supplier Surgi C Group.

 

Adam Reynolds
Non Executive Director

. Former stockbroker with over 35 years’ experience within the UK financial services sector
. Founded Hansard Group Plc which was admitted to trading on AIM in 2000
. Currently a director of several AIM traded companies - non-executive director of EKF Diagnostics Holdings Plc, Optibiotix Plc and Premaitha Health Plc
. Director of a number of private companies

 

Neil Mesher
Non-exectuive Director

Neil has more than 25 years of global experience within the healthcare and consumer electronics industries. He is currently CEO of Philips for the UK and Ireland and is on the Board of the Association of British Healthcare Industries (ABHI), from which he led the industry’s response to the NHS’s “5 Year Forward View”, assessing opportunities for greater integration between industry and the healthcare system. Neil is also a member of the Governments Life Science Industrial Strategy Board, representing the interests of the medical technology sector with other senior leaders from across healthcare.

Issued share capital will consist of 109,625,247 ordinary shares of 2.5p each

Percentage of AIM securities not in public hands is 2.88 per cent.

This information was last updated on 8 March 2017

Shareholdings holding over 3%

Shareholder Ordinary Shares Issued Share Capital (%)
Mercia Technologies PLC 19,999,999 18.32
Finance Yorkshire Seedcorn Fund 12,699,997 11.63
Angel CoFund 11,668,267 10.69

Directors Shareholding

Shareholder Ordinary Shares Issued Share Capital (%)
A Reynolds 1,155,555 1.06
E Henau 293,333 0.267
B Spurrier 246,057 0.23
N Herbert 1,530,729 1.40

 

GENERAL ENQUIRIES

The Exchange
Colworth Park
Sharnbrook
Bedfordshire
MK44 1LQ

Telephone: 01234 866601
General Email: [email protected]

 

MEDIA ENQUIRIES

Yellow Jersey PR Limited
1st Floor
30 Stamford Street,
London
SE1 9LQ

Yellow Jersey PR Ltd
Telephone: +44 (0)203 735 8825.

Nominated Adviser

SPARK Advisory Partners Limited
5 St John’s Lane
Farringdon
London EC1M 4BH

Broker

Beaufort Securities Limited
Beaufort Securities Ltd
131 Finsbury Pavement
London EC2A 1NT

Solicitors to the Company

BPE Solicitors LLP
St James House
St James Square
Cheltenham GL50 3PR

Solicitors to the Nominated Adviser

Addleshaw Goddard LLP
Milton Gate
Chiswell Street
London EC1Y 4AG

Reporting Accountant & Auditor

Jeffreys Henry LLP
5 – 7 Cranwood Street
Finsgate
London EC1V 9EE

Registrar

Neville Registrars Limited
Neville House
18 Laurel Lane
Halesowen B63 3DA

View full CPT profile View Profile
View All

Market Reports Including CPT

VIEW ALL

Executive video interviews

VIEW ALL VIDEOS

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.